Biotech News

Corvus Pharmaceuticals to Announce Results from Cohort 4 of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis

Corvus Pharmaceuticals (CRVS)Corvus Pharmaceuticals2026-06-25 13:46 ESTClinical readout

Company to host conference call and webcast on Tuesday, January 20, 2026 at 8:00 am ET / 5:00 am PT SOUTH SAN FRANCISCO, Calif. , Jan. 16, 2026 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, announced that it will host a conference call

Open original release

Related news

CRVSCorvus Pharmaceuticals2026-06-25 13:46 EST

Corvus Pharmaceuticals Announces Additional Investment in Angel Pharmaceuticals to Advance the Development of Soquelitinib in China

CRVSCorvus Pharmaceuticals2026-06-25 13:46 EST

Corvus Pharmaceuticals to Present at the 2026 Jefferies Global Healthcare Conference and Goldman Sachs 47th Annual Global Healthcare Conference

CRVSCorvus Pharmaceuticals2026-06-25 13:46 EST

Corvus Pharmaceuticals Presents Soquelitinib Phase 1 Atopic Dermatitis Data at the Society for Investigative Dermatology (SID) Annual Meeting

CRVSCorvus Pharmaceuticals2026-06-25 13:46 EST

Corvus Pharmaceuticals Provides Business Update and Reports First Quarter 2026 Financial Results

CRVSCorvus Pharmaceuticals2026-06-25 13:46 EST

Corvus Pharmaceuticals Announces Positive Data from Cohort 4 Confirming Results for Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis

CRVSCorvus Pharmaceuticals2026-06-25 13:46 EST

Corvus Pharmaceuticals Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

CRVSCorvus Pharmaceuticals2026-06-25 13:46 EST

Corvus Pharmaceuticals Announces Pricing of Upsized Public Offering of Common Stock

CRVSCorvus Pharmaceuticals2026-06-25 13:46 EST

Corvus Pharmaceuticals Announces Closing of Upsized Public Offering of Common Stock and Full Exercise of the Underwriters’ Option to Purchase Additional Shares, Generating Gross Proceeds of Approximately $201M

CRVSCorvus Pharmaceuticals2026-06-25 13:46 EST

Corvus Pharmaceuticals to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference

CRVSCorvus Pharmaceuticals2026-06-25 13:46 EST

Corvus Pharmaceuticals to Provide Business Update and Fourth Quarter and Full Year 2025 Financial Results on March 12, 2026

View all latest news

Corvus Pharmaceuticals

Corvus Pharmaceuticals is a biopharmaceutical company focused on pipeline execution and catalyst-driven growth, with investors tracking how data, regulatory milestones, and launch timing reshape the investment case.

Recent company news

CRVSZimmer Biomet2026-07-14 12:13 EST

Zimmer Biomet Names Chintan Desai President of Asia Pacific Region

CRVSZimmer Biomet2026-07-13 12:14 EST

Zimmer Biomet Announces Webcast and Conference Call of Second Quarter 2026 Financial Results

CRVSBMYBristol-Myers Squibb Company2026-07-13 10:59 EST

U.S. Food and Drug Administration Accepts Bristol Myers Squibb's New Drug Application for Mezigdomide in Patients with Relapsed or Refractory Multiple Myeloma

CRVSGSK plc2026-07-13 07:00 EST

Jemperli (dostarlimab) achieves sustained clinical complete responses in dMMR/MSI-H locally advanced rectal cancer

CRVSMerck2026-07-10 19:01 EST

FDA Approves KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), Each With Padcev® (enfortumab vedotin-ejfv), as Treatment Before and After Surgery for Adults With Muscle-Invasive Bladder Cancer (MIBC)

Stock data

Close: 14.71 USD
Market cap: 1.32B USD
Exchange: NASDAQ
Sector: Biotechnology
Location: United States